ContextVision
- Home ›
- NO ›
- Healthcare
ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers worldwide. The last earnings update was 51 days ago. More info.
Add to Portfolio Compare Print
COV Share Price and Events
7 Day Returns
1 Year Returns
COV Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| ContextVision (COV) | 2.9% | -6.5% | 16.8% | 35.4% | 150.9% | 358.3% |
| Europe Healthcare Services | 0.3% | 2% | 9.7% | 12.3% | 31.9% | 105.7% |
| NO Market | -1.3% | -4.9% | -3.7% | -4.3% | 26.9% | 14.7% |
1 Year Return vs Industry and Market
- COV outperformed the Healthcare Services industry which returned 12.3% over the past year.
- COV outperformed the Market in Norway which returned -4.3% over the past year.
COV Value
Is ContextVision undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
ContextVision
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for ContextVision.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 2 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.6% |
| Perpetual Growth Rate | 10-Year NO Government Bond Rate | 1.8% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year NO Govt Bond Rate | 1.8% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Services Unlevered Beta | Simply Wall St/ S&P Global | 1.23 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.226 (1 + (1- 22%) (0%)) |
1.152 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.15 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.76% + (1.152 * 5.96%) |
8.62% |
Discounted Cash Flow Calculation for OB:COV using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for ContextVision is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (SEK, Millions) | Source |
Present Value Discounted (@ 8.62%) |
|
|---|---|---|---|
| 2019 | -5.10 | Analyst x1 | -4.69 |
| 2020 | -2.40 | Analyst x1 | -2.03 |
| 2021 | 38.00 | Analyst x1 | 29.65 |
| 2022 | 65.45 | Est @ 72.25% | 47.02 |
| 2023 | 98.90 | Est @ 51.1% | 65.40 |
| 2024 | 134.80 | Est @ 36.3% | 82.07 |
| 2025 | 169.77 | Est @ 25.94% | 95.15 |
| 2026 | 201.49 | Est @ 18.68% | 103.96 |
| 2027 | 228.91 | Est @ 13.61% | 108.73 |
| 2028 | 251.92 | Est @ 10.05% | 110.16 |
| Present value of next 10 years cash flows | SEK635.40 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= SEK251.92 × (1 + 1.76%) ÷ (8.62% – 1.76%) |
SEK3,734.96 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= SEK3,734.96 ÷ (1 + 8.62%)10 |
SEK1,633.21 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= SEK635.40 + SEK1,633.21 |
SEK2,268.61 |
| Equity Value per Share (SEK) |
= Total value / Shares Outstanding
= SEK2,268.61 / 7.74 |
SEK293.22 |
| Calculation | Result | |
|---|---|---|
| Exchange Rate | SEK/NOK
(Reporting currency to currency of OB:COV) |
0.911 |
| Value per Share (NOK) |
= Value per Share in SEK x Exchange Rate (SEK/NOK)
= SEK293.22 x 0.911 |
NOK267.14 |
| Value per share (NOK) | From above. | NOK267.14 |
| Current discount | Discount to share price of
NOK71.50
= -1 x (NOK71.50 - NOK267.14) / NOK267.14 |
73.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- ContextVision's share price is below the future cash flow value, and at a moderate discount (> 20%).
- ContextVision's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for ContextVision's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
ContextVision's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in SEK | SEK-0.15 |
| OB:COV Share Price ** | OB (2019-05-24) in NOK | NOK71.5 |
| OB:COV Share Price converted to SEK reporting currency | Exchange rate (NOK/ SEK) 1.098 | SEK78.48 |
| Europe Healthcare Services Industry PE Ratio | Median Figure of 20 Publicly-Listed Healthcare Services Companies | 28.95x |
| Norway Market PE Ratio | Median Figure of 133 Publicly-Listed Companies | 13.7x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of ContextVision.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = OB:COV Share Price ÷ EPS (both in SEK) = 78.48 ÷ -0.15 |
-515.01x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- ContextVision is loss making, we can't compare its value to the Europe Healthcare Services industry average.
- ContextVision is loss making, we can't compare the value of its earnings to the Norway market.
Price based on expected Growth
Does
ContextVision's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -515.01x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts |
68%per year |
| Europe Healthcare Services Industry PEG Ratio | Median Figure of 12 Publicly-Listed Healthcare Services Companies | 2.26x |
| Norway Market PEG Ratio | Median Figure of 102 Publicly-Listed Companies | 0.92x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for ContextVision, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
ContextVision's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in SEK | SEK7.57 |
| OB:COV Share Price * | OB (2019-05-24) in NOK | NOK71.5 |
| OB:COV Share Price converted to SEK reporting currency | Exchange rate (NOK/ SEK) 1.098 | SEK78.48 |
| Europe Healthcare Services Industry PB Ratio | Median Figure of 40 Publicly-Listed Healthcare Services Companies | 2.46x |
| Norway Market PB Ratio | Median Figure of 212 Publicly-Listed Companies | 1.14x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = OB:COV Share Price ÷ Book Value per Share (both in SEK) = 78.48 ÷ 7.57 |
10.37x |
* Primary Listing of ContextVision.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- ContextVision is overvalued based on assets compared to the Europe Healthcare Services industry average.
Value checks
We assess ContextVision's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check) ContextVision has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
COV Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- ContextVision's earnings growth is expected to exceed the low risk savings rate of 1.8%.
Growth vs Market Checks
- ContextVision's earnings growth is expected to exceed the Norway market average.
- ContextVision's revenue growth is expected to exceed the Norway market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| OB:COV Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts | 68% |
| OB:COV Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts | 19.3% |
| Europe Healthcare Services Industry Earnings Growth Rate | Market Cap Weighted Average | 11.8% |
| Europe Healthcare Services Industry Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
| Norway Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| Norway Market Revenue Growth Rate | Market Cap Weighted Average | 3.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Date (Data in SEK Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 227 | 1 | ||
| 2022-12-31 | 209 | 1 | ||
| 2021-12-31 | 149 | 73 | 34 | 2 |
| 2020-12-31 | 116 | 32 | 16 | 2 |
| 2019-12-31 | 95 | 26 | 13 | 2 |
| Date (Data in SEK Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 91 | 5 | -1 |
| 2018-09-30 | 85 | 5 | -2 |
| 2018-06-30 | 82 | 5 | -3 |
| 2018-03-31 | 82 | 4 | -2 |
| 2017-12-31 | 81 | 2 | -2 |
| 2017-09-30 | 83 | 5 | -1 |
| 2017-06-30 | 85 | 1 | 1 |
| 2017-03-31 | 81 | 4 | 0 |
| 2016-12-31 | 82 | 10 | 4 |
| 2016-09-30 | 76 | 6 | 3 |
| 2016-06-30 | 73 | 10 | 4 |
| 2016-03-31 | 72 | 12 | 5 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
All data from ContextVision Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in SEK Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | ||||
| 2022-12-31 | ||||
| 2021-12-31 | 4.37 | 7.41 | 1.32 | 2.00 |
| 2020-12-31 | 2.09 | 3.24 | 0.94 | 2.00 |
| 2019-12-31 | 1.64 | 2.23 | 1.05 | 2.00 |
| Date (Data in SEK Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.15 |
| 2018-09-30 | -0.30 |
| 2018-06-30 | -0.45 |
| 2018-03-31 | -0.28 |
| 2017-12-31 | -0.22 |
| 2017-09-30 | -0.17 |
| 2017-06-30 | 0.13 |
| 2017-03-31 | 0.06 |
| 2016-12-31 | 0.55 |
| 2016-09-30 | 0.36 |
| 2016-06-30 | 0.48 |
| 2016-03-31 | 0.64 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess ContextVision's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
ContextVision has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
COV Past Performance
How has ContextVision performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- ContextVision does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare ContextVision's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare ContextVision's 1-year growth to the Europe Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
All data from ContextVision Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in SEK Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 90.90 | -1.18 | 33.15 | |
| 2018-09-30 | 85.44 | -2.29 | 31.92 | |
| 2018-06-30 | 81.59 | -3.47 | 29.75 | |
| 2018-03-31 | 82.46 | -2.18 | 29.37 | |
| 2017-12-31 | 80.51 | -1.71 | 27.94 | |
| 2017-09-30 | 82.90 | -1.29 | 28.35 | |
| 2017-06-30 | 85.20 | 1.04 | 28.24 | |
| 2017-03-31 | 80.76 | 0.49 | 25.53 | |
| 2016-12-31 | 81.92 | 4.25 | 23.37 | |
| 2016-09-30 | 75.81 | 2.82 | 20.83 | |
| 2016-06-30 | 72.52 | 3.71 | 18.84 | |
| 2016-03-31 | 72.28 | 4.97 | 18.06 | |
| 2015-12-31 | 72.24 | 5.34 | 18.39 | |
| 2015-09-30 | 69.72 | 5.40 | 16.88 | |
| 2015-06-30 | 67.46 | 3.99 | 17.62 | |
| 2015-03-31 | 65.21 | 5.39 | 18.17 | |
| 2014-12-31 | 64.40 | 5.42 | 18.86 | |
| 2014-09-30 | 63.63 | 7.52 | 18.63 | |
| 2014-06-30 | 64.72 | 9.07 | 18.03 | |
| 2014-03-31 | 62.91 | 5.45 | 19.30 | |
| 2013-12-31 | 61.28 | 4.88 | 18.57 | |
| 2013-09-30 | 66.32 | 3.61 | 19.81 | |
| 2013-06-30 | 65.79 | 2.56 | 20.13 | |
| 2013-03-31 | 67.84 | 1.15 | 22.99 | |
| 2012-12-31 | 67.12 | 0.62 | 23.19 | |
| 2012-09-30 | 63.77 | 0.01 | 22.47 | |
| 2012-06-30 | 62.14 | -0.02 | 22.03 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if ContextVision has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if ContextVision has efficiently used its assets last year compared to the Europe Healthcare Services industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if ContextVision improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess ContextVision's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
ContextVision has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
COV Health
How is ContextVision's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up ContextVision's finances.
The net worth of a company is the difference between its assets and liabilities.
- ContextVision is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- ContextVision's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- ContextVision has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from ContextVision Company Filings, last reported 4 months ago.
| Date (Data in SEK Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 58.56 | 0.00 | 37.95 |
| 2018-09-30 | 55.55 | 0.00 | 40.80 |
| 2018-06-30 | 54.45 | 0.00 | 37.04 |
| 2018-03-31 | 55.58 | 0.00 | 40.73 |
| 2017-12-31 | 59.35 | 0.00 | 40.33 |
| 2017-09-30 | 57.79 | 0.00 | 42.82 |
| 2017-06-30 | 58.77 | 0.00 | 37.81 |
| 2017-03-31 | 58.80 | 0.00 | 40.95 |
| 2016-12-31 | 61.43 | 0.00 | 42.91 |
| 2016-09-30 | 59.05 | 0.00 | 38.96 |
| 2016-06-30 | 57.52 | 0.00 | 38.58 |
| 2016-03-31 | 58.17 | 0.00 | 38.03 |
| 2015-12-31 | 57.04 | 0.00 | 35.64 |
| 2015-09-30 | 56.05 | 0.00 | 35.66 |
| 2015-06-30 | 53.65 | 0.00 | 32.09 |
| 2015-03-31 | 52.64 | 0.00 | 30.26 |
| 2014-12-31 | 50.75 | 0.00 | 31.13 |
| 2014-09-30 | 50.49 | 0.00 | 33.54 |
| 2014-06-30 | 49.19 | 0.00 | 29.18 |
| 2014-03-31 | 47.06 | 0.00 | 31.76 |
| 2013-12-31 | 45.53 | 0.00 | 29.16 |
| 2013-09-30 | 42.79 | 0.00 | 26.85 |
| 2013-06-30 | 40.39 | 0.00 | 23.59 |
| 2013-03-31 | 42.21 | 0.00 | 27.21 |
| 2012-12-31 | 41.05 | 0.00 | 24.72 |
| 2012-09-30 | 39.62 | 0.00 | 22.46 |
| 2012-06-30 | 38.22 | 0.00 | 17.87 |
- ContextVision has no debt.
- ContextVision has not taken on any debt in the past 5 years.
- ContextVision has no debt, it does not need to be covered by operating cash flow.
- ContextVision has no debt, therefore coverage of interest payments is not a concern.
Financial health checks
We assess ContextVision's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) ContextVision has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
COV Dividends
What is ContextVision's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
NOK2,000 of
ContextVision
shares you are expected to receive
NOK0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate ContextVision's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate ContextVision's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Europe Healthcare Services Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 1.5% |
| Norway Market Average Dividend Yield | Market Cap Weighted Average of 109 Stocks | 4.5% |
| Norway Minimum Threshold Dividend Yield | 10th Percentile | 1.8% |
| Norway Bottom 25% Dividend Yield | 25th Percentile | 2.5% |
| Norway Top 25% Dividend Yield | 75th Percentile | 6.5% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in SEK) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
| Date (Data in SEK) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2009-10-12 | 0.000 | 0.000 |
| 2009-08-20 | 0.000 | 0.000 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as ContextVision has not reported any payouts.
- Unable to verify if ContextVision's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess ContextVision's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can ContextVision afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) ContextVision has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
COV Management
CEO
| TENURE AS CEO | 0.1 years |
CEO Bio
Mr. Fredrik Palm has been the Chief Executive Officer of ContextVision AB (publ) since April 1, 2019. He was Vice President of Sales at ContextVision AB (publ) since January 2012 until April 1, 2019. He served as a Vice President of OEM Business at ContextVision AB. Mr. Palm has over 20 years of experience from companies within life science, where he has mainly worked from the marketing and sales side in a global perspective. Since 2012, he has led the marketing and sales activities at ContexVision, where revenue during the period has increased from SEK 60 million to more than SEK 90 million last year. After many years at Waters Corporation, he moved on to several sales and marketing positions at medical device companies, focusing on international expansion. His experience covers international sales, marketing and business development as well as concepts for value based communication. He has complemented his engineer background with studies in business management and strategic marketing.
CEO Compensation
- Insufficient data for Fredrik to compare compensation growth.
- Insufficient data for Fredrik to establish whether their remuneration is reasonable compared to companies of similar size in Norway.
Management Team Tenure
Average tenure of the ContextVision management team in years:
- The tenure for the ContextVision management team is about average.
Management Team
Sven Günther-Hanssen
Co-Founder & Director
64
Martin Hedlund
Co-Founder
SEK2M
66
20.3 yrs
Fredrik Palm
Chief Executive Officer
0.1 yrs
Ann-Charlotte Linderoth
Chief Financial Officer
4.1 yrs
Board of Directors Tenure
Average tenure and age of the ContextVision board of directors in years:
- The tenure for the ContextVision board of directors is about average.
Board of Directors
Erik Danielsen
Chairman of the Board
SEK300K
55
9.3 yrs
Sven Günther-Hanssen
Co-Founder & Director
64
Martin Hedlund
Co-Founder
SEK2M
66
22.3 yrs
Karin Bernadotte
Director
SEK200K
55
8.3 yrs
Fredrik Pontén
Digital Pathology Advisory Board Member
1.5 yrs
Junya Fukuoka
Digital Pathology Advisory Board Member
1.5 yrs
Anil Parwani
Digital Pathology Advisory Board Member
Jeroen van der Laak
Digital Pathology Advisory Board Member
Dan Ciresan
Digital Pathology Advisory Board Member
Henning Müller
Digital Pathology Advisory Board Member
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (NOK) | Value (NOK) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 09. Dec 18 | Sell | Anita Tollstadius | Individual | 06. Dec 18 | 06. Dec 18 | -225 | NOK55.02 | NOK-12,380 | ||
Management checks
We assess ContextVision's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) ContextVision has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
COV News
Simply Wall St News
How Much Of ContextVision AB (publ) (OB:COV) Do Insiders Own?
As Charlie Munger said 'Show me the incentive and I will show you the outcome.' ContextVision is a smaller company with a market capitalization of øre534m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for ContextVision OB:COV Ownership Summary, May 15th 2019 What Does The Institutional Ownership Tell Us About ContextVision? … Private Company Ownership It seems that Private Companies own 43%, of the COV stock.
Simply Wall St - – Full articleDoes ContextVision AB (publ)'s (OB:COV) CEO Salary Compare Well With Others?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Anita Tollstadius's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below kr1.9b
Simply Wall St - – Full articleWhat Kind Of Shareholder Owns Most ContextVision AB (publ) (OB:COV) Stock?
A look at the shareholders of ContextVision AB (publ) (OB:COV) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … ContextVision is not a large company by global standards.
Simply Wall St - – Full articleIs ContextVision AB (publ) (OB:COV) A Financially Sound Company?
The direct benefit for ContextVision AB (publ) (OB:COV), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.
Simply Wall St - – Full articleShould You Worry About ContextVision AB (publ)'s (OB:COV) CEO Pay Cheque?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Anita Tollstadius's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that ContextVision AB (publ) has a market cap of øre450m, and is paying total annual CEO compensation of kr2.3m.
Simply Wall St - – Full articleIs There An Opportunity With ContextVision AB (publ)'s (OB:COV) 40.83% Undervaluation?
How far off is ContextVision AB (publ) (OB:COV) from its intrinsic value? … by taking the expected future cash flows and discounting them to their present value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model
Simply Wall St - – Full articleWhy I Like ContextVision AB (publ) (OB:COV)
As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … financial health as well as
Simply Wall St - – Full articleShould You Be Concerned About ContextVision AB (publ)'s (OB:COV) Investors?
Today, I will be analyzing ContextVision AB (publ)’s (OB:COV) recent ownership structure, an important but not-so-popular subject among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices.
Simply Wall St - – Full articleLooking At ContextVision AB (publ) (OB:COV) From All Angles
ContextVision AB (publ) (OB:COV) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … Below is a brief commentary on these key aspects.
Simply Wall St - – Full articleWho Are The Top Investors In ContextVision AB (publ) (OB:COV)?
Check out our latest analysis for ContextVision OB:COV Ownership_summary May 16th 18 Institutional Ownership In COV's case, institutional ownership stands at 15.79%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … With this size of ownership in COV, this ownership class can affect the company's business strategy. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.
Simply Wall St - – Full articleCOV Company Info
Description
ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers worldwide. It operates through two segments, Medical Imaging and Digital Pathology. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include US PLUSView, an image enhancement software product for women’s health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; GOPiCE, a technology for volumetric image enhancement in real-time; and REALiCE, a volume enhancement and rendering solution for visualization. The company also provides Altumira/Altumira Plus, a solution for various digital radiography systems; GOPView XR2Plus for x-ray systems for human and veterinary examinations; Orthopedic Package for orthopedic imaging; and GOPView iRVUltra, a software for noise suppression, edge, and contrast enhancement in real time. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; GOPView Mammo3, an image enhancement software for screening and diagnostic mammography; and INIFY Prostate, an AI-based software that outlines and quantifies suspected cancerous areas in a series of prostate biopsies. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.
Details
| Name: | ContextVision AB (publ) |
| COV | |
| Exchange: | OB |
| Founded: | 1983 |
| NOK553,177,625 | |
| 7,736,750 | |
| Website: | http://www.contextvision.com |
| Address: |
ContextVision AB (publ) Klara Norra Kyrkogata 31, Stockholm, Stockholm County, 111 22, Sweden |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| OB | COV | Common Shares | Oslo Bors | NO | NOK | 18. Mar 1997 | |
| BATS-CHIXE | COVO | Common Shares | BATS 'Chi-X Europe' | GB | NOK | 18. Mar 1997 |
Number of employees
Current staff
Industry
| Health Care Technology | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/25 20:43 |
| End of day share price update: | 2019/05/24 00:00 |
| Last estimates confirmation: | 2019/04/30 |
| Last earnings filing: | 2019/04/04 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
